Volumizing effects of a smooth, highly cohesive, viscous 20-mg/mL hyaluronic acid volumizing filler: prospective European study
© Hoffmann and the Juvéderm Voluma Study Investigators Group; licensee BioMed Central Ltd. 2009
Received: 11 December 2008
Accepted: 27 August 2009
Published: 27 August 2009
Facial volume loss contributes significantly to facial aging. The 20-mg/mL hyaluronic acid (HA) formulation used in this study is a smooth, highly cohesive, viscous, fully reversible, volumizing filler indicated to restore facial volume. This first prospective study evaluated use in current aesthetic clinical practice.
A pan-European evaluation conducted under guidelines of the World Association of Opinion and Marketing Research, the trial comprised a baseline visit (visit 1) and a follow-up (visit 2) at 14 ± 7 days posttreatment. Physicians photographed patients at each visit. Each patient was treated with the 20-mg/mL HA volumizing filler as supplied in standard packaging. Procedural details, aesthetic outcomes, safety, and physician and patient ratings of their experience were recorded.
Fifteen physicians and 70 patients (91% female; mean age: 50 years) participated. Mean volume loss at baseline was 3.7 (moderate) on the Facial Volume Loss Scale. Local anesthesia was used in 64.3% of cases. Most injections (85%) were administered with needles rather than cannulas. Of the 208 injections, 59% were in the malar region, primarily above the periosteum. Subcutaneous injections were most common for other sites. The mean total injection volume per patient was 4.6 mL. The mean volume loss score declined significantly (P < .001) to 2.1 at visit 2. On the Global Aesthetic Improvement Scale, 88% and 76% of the treatments were rated very much improved or much improved by physicians and patients, respectively. Of the physicians, 95.6% rated this HA filler as very or fairly easy to use. Similarly, 92% of patients were very likely or quite likely to return for treatment; nearly all (98%) would recommend this treatment to friends. Transient (mean duration: 5.5 days) injection-site adverse events (AEs) occurred in 24 patients. Bruising was the most common AE.
The 20-mg/mL smooth, highly cohesive, viscous, volumizing HA filler was effective, well tolerated, and easy to use in current clinical practice. Participants were very likely to recommend this product to colleagues and friends, and patients would be very or quite likely to request this product for future treatments.
Facial aging is a consequence of multiple, interacting intrinsic and extrinsic factors. Sun exposure, or photoaging, contributes importantly to the intrinsic changes associated with aging. These changes have been described using the Glogau photoaging classification, which focuses on the degree of wrinkling. Another factor in the appearance of facial aging is the lifelong activity of the muscles of facial expression, which produce the dynamic and, ultimately, static facial lines and folds. It has also long been recognized that gravity exerts a toll on the facial structures as tissue loses its elasticity and becomes less able to resist stretching.
Volume deficits resulting from the loss and repositioning of facial fat, as well as from skeletal remodeling, are now increasingly appreciated as a fundamental component of facial aging.[1, 4, 5] The younger face is characterized by the harmony and balance captured in the classic heart shape or inverted triangle.[1, 6] The reversal of this "triangle of beauty" as aging proceeds and as proportions rearrange is considered generally less aesthetically appealing. With these changes, the convexities typical of a youthful appearance tend to flatten and droop.
Recognition of the key role of volume loss in facial aging has resulted in what has been called a paradigm shift in facial rejuvenation, influencing both the types and extent of surgical procedures, as well as the way in which minimally invasive approaches are employed. Facial rejuvenation has moved beyond wrinkle effacement and surgical facelifts to an approach that relaxes muscles and volumizes, shapes, recontours, and retexturizes. In combination with preventive skin care measures, this comprehensive, multimodal approach permits clinicians to develop aesthetic treatment plans tailored to individual patient needs and designed to produce a natural, relaxed appearance.[6, 8]
Subdermal fillers can form a cornerstone of the new facial rejuvenation paradigm. The product that was the subject of this study, a 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler, shares many of the properties of its wider family of 24-mg/mL smooth, cohesive HA fillers, but also has unique physical and chemical properties that make it ideally suited for volumizing and contouring. These products are smooth, cohesive HA fillers as a result of the manufacturing process in which they are homogenized rather than sieved to produce the final product. This is in comparison with hard and granular formulations produced by the sieving process. [9, 10] The 20-mg/mL smooth, cohesive HA filler was designed to be more viscous and robust with a higher lift capacity than other members of its family. The 20-mg/mL smooth, cohesive HA filler is derived primarily from low-molecular-weight (LMW) HA. Its HA concentration, 20 mg/mL, and its water binding capacity is similar to that of other 24-mg/mL smooth, cohesive products. Crosslinking of LMW HA results in significantly increased viscosity. As a result, the final product has very high viscosity and cohesivity while remaining soft and readily extrudable. It also retains the properties of reversibility, in the event of overcorrection or complications, and resorbability. At the same time, the product has the potential for long-term persistence in tissue.
The 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler has been evaluated retrospectively in patients with age-related volume loss and prospectively in patients with human immunodeficiency virus (HIV)-associated lipoatrophy.[1, 11] The results of both of these studies demonstrated that the 20-mg/mL smooth, cohesive HA volumizing filler was highly effective and well tolerated. Aesthetic improvements were also durable, with reported longevities of at least 12 and up to 18 months based on the defined durations of each study.[1, 11]
In this article, we report on the first prospective trial designed to assess how the 20-mg/mL smooth, cohesive HA volumizing filler is used in current clinical practice. Specific objectives were to characterize the aesthetic benefit and safety profile of the 20-mg/mL smooth, cohesive HA volumizing filler; to evaluate patient and clinician perspectives on the product; to assess practice preferences, including similarities, and differences among specialties; and to derive practice recommendations.
This was a prospective, open-label, nonrandomized study in which a 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler (Juvéderm™ VOLUMA™, Allergan, Pringy, France) was evaluated within its indicated use of restoring facial volume. The study was funded by Allergan, Inc. This Europe-wide evaluation was conducted under the guidelines of the World Association of Opinion and Marketing Research (ESOMAR) to evaluate current usage of the 20-mg/mL smooth, cohesive HA volumizing filler in European countries in which the product is CE-marked or licensed and available. Evaluations took place within standard practice procedures without the inclusion of any additional monitoring or diagnostic procedures. The conduct of the trial complied with the provisions of the Helsinki Declaration for studies in humans; however, it was not a clinical trial as such. As a market research evaluation of a CE-marked device within intended use, regulatory approval is not required, and therefore, ethics approval was not sought.
Men and women of at least 30 years of age who requested treatment for facial volume loss and who were able to provide informed consent were eligible for participation. They were required to have a facial volume loss score of at least 2 on the 5-point Facial Volume Loss Scale. Prospective patients were excluded if they were participants in any ongoing clinical trial or had any conditions contraindicating the use of the 20-mg/mL smooth, cohesive HA volumizing filler, such as a tendency to develop hypertrophic scars, known hypersensitivity to HA, or pregnancy or lactation. The presence of inflamed or infected skin (eg, acne, herpes) in the planned treatment areas precluded participation. Also excluded were patients who had received any previous treatment with a permanent or semipermanent filler or implant within the preceding 12 months.
Investigators injected the 20-mg/mL smooth, cohesive HA volumizing filler with either a cannula or needle, according to their usual practices. They determined the volume to be injected based on patient assessment using the Facial Volume Loss Scale (1 = mild, 2 = intermediate between mild and moderate, 3 = moderate, 4 = intermediate between moderate and severe, 5 = severe) and their aesthetic judgment. Touch-ups could be performed at visit 2 based on the judgment of the investigator. The use of anesthetic also depended upon the preferences and usual practice of the treating physician.
Data Collection and Study Endpoints
Investigators recorded each patient's age, sex, and baseline volume loss according to the Facial Volume Loss Scale. At the time of treatment, investigators recorded the type(s) of anesthesia, the type and size of the injection device (needle or cannula), the injection sites and volume per site, the total volume, and the injection plane and pattern. They also assessed the ease of injection, sculpting, and shaping with the 20-mg/mL smooth, cohesive HA volumizing filler, and recorded their posttreatment instructions for patients.
Effectiveness was assessed at visit 2 and was based on investigator-assessed changes from baseline on the Facial Volume Loss Scale and on investigator and patient ratings on the Global Aesthetic Improvement Scale (GAIS), which includes 5 categories ranging from very much improved to worse. The need for touch-ups was evaluated. This included the reason, the site, the injection technique and plane, and the volume. Safety was monitored by recording the occurrence of any adverse event (AE) that followed treatment, including its site, severity, and duration. Severity was determined by the usual clinical criteria of each individual investigator. At this visit, investigators also noted their willingness to recommend the 20-mg/mL smooth, cohesive HA volumizing filler to their colleagues.
At visit 2, patients completed their questionnaire, recording their satisfaction with the overall cosmetic effect, their likelihood of returning for additional treatments with the 20-mg/mL smooth, cohesive HA volumizing filler, and their willingness to recommend it to their friends.
The data were summarized with descriptive statistics (eg, percentages, means, ranges). The differences between pretreatment and posttreatment mean Facial Volume Loss Scale scores were analyzed using a t-test.
Patient Baseline and Demographic Data (N = 70)
Ascher Scale (mean score)
Ascher Scale (score distributions)*
Grade 2: 44%
Grade 3: 34%
Grade 4: 14%
Grade 5: 3%
Treatment and Practice Characteristics
Type of Anesthesia
Anesthesia (n = 56)
Regional or Block
Type of Injection Device
Injection Sites and Volumes*
Injection Sites (Mean Volume/Side)
208 Sites Recorded
All injections were in the deep dermis or above the periosteum as recommended in the product instructions for use. In the malar area, the majority of injections were subcutaneous (39%) or above the periosteum (40%). In other areas, subcutaneous injections predominated. Linear threading was the most common injection technique for the malar area (36%), chin (59%), and nasolabial folds (51%). Fanning was the most common technique used for the temporal area (58%) and other areas (57%.) Some differences among specialties were noted. Dermatologists used cross-hatching 47% of the time, linear threading 28% of the time, and a combination of techniques 40% of the time. Plastic surgeons used linear threading 37% of the time, followed by fanning (24%), cross-hatching (16%), and combinations (18%). Aesthetic practitioners used primarily cross-hatching (48%), then fanning (22%), and combinations (16%).
Nine patients (13%) were deemed to require touch-ups. The most common reason was the need for additional volume. Two touch-ups were needed to correct an uneven result. For the right side, 8 patients were treated with an additional mean volume of 0.8 mL. Five patients required an additional mean volume of 0.7 mL on the left side. The total mean additional volume added at visit 2 was 1.5 mL.
Specific posttreatment recommendations varied considerably across participating physicians but were generally consistent with typical practice for any facial filler. The more commonly mentioned recommendations to patients were to avoid massaging the area for at least 24 hours, sauna treatments, vigorous sports, sleeping face-down, and anticoagulant medications such as aspirin. Patients were also cautioned to expect the possibility of bruising and swelling.
Number of Patients (n = 24)
Pain and bruising
Bruising and swelling
Pain and swelling
Bruising and bleeding
Infection and swelling
For the patient who experienced posttreatment infection, previous aesthetic treatments included onabotulinumtoxintypeA (BOTOX®), synthetic polyacrylamide gel polymer filler (Bio-Alcamid™; Rofil), and lip augmentation with synthetic polyacrylamide gel polymer filler (Beautical 2®; Rofil). Prior polyacrylamide treatments were not disclosed to the treating physician. Four months after injection with 2 mL of the 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler into the malar area and chin; a biofilm and abscess developed. The event was determined to be unrelated to treatment with the 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler. The patient was treated with amoxicillin/clavulanic potassium (Augmentin®) 3 times daily for 10 days, and with ibuprofen 600 mg, 3 times daily for 7 days. The site was evacuated and cleansed, and the symptoms fully resolved without further sequelae.
Physician Experience and Perspectives on Treatment
Patient Experience and Perspectives
To our knowledge, this was the first prospective evaluation on the use of a 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler in current aesthetic clinical practice. The study was designed to characterize treatment techniques, assess effectiveness and safety, and evaluate physician and patient perspectives on the experience. Patients with facial volume loss of at least 2 on the Facial Volume Loss Scale were eligible. A total of 70 patients and 15 investigators (dermatologists, plastic surgeons, and aesthetic practitioners) participated.
Most injections were performed under local anesthesia and needles were used in the majority of treatments, although both needles and cannulas will be available in the supplied standard product package. The most common treatment area was the malar region with a mean total injection volume per patient of 4.6 mL. Regardless of technique, treatment area, or specialty, the vast majority of physicians found the 20-mg/mL smooth, cohesive HA volumizing filler to be easy to inject, sculpt, and mold.
Treatment with the 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler resulted in statistically significant improvements in facial volume. Indeed, 70% of patients were rated as having a low degree of volume loss posttreatment, a substantial change from pretreatment. The vast majority of patients and physicians rated the changes in appearance as much or very improved, and the majority of patients did not experience any AEs. Based on patient ratings, including their high likelihood of returning for treatment and of recommending it for friends, the outcomes provided a high degree of patient satisfaction, one of the most important outcomes in aesthetic medicine. The results from this study are consistent with those of the first retrospective analysis of the 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler (Juvéderm™ VOLUMA™) in a case series of 102 patients with age-related facial volume loss. This retrospective study, however, differed from the current study in the volume loss scale that was used, and that patients were evaluated at 30 days after treatment to allow all potential treatment site responses to fully subside. Data from other published studies also reveal that the 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler provides a durable response of at least 12 to 18 months when used for restoring facial volume lost through aging or resulting from HIV-associated lipoatrophy.[1, 11] It is very important to note that there were no instances of migration or mobility of the product, nor any irregularities in appearance in the injection area. In contrast, clinical experience with the 20-mg/mL 1,000 particle, granular consistency HA filler (Restylane® SubQ) has revealed migration from the injection area, which is speculated to be the result of its low cohesivity and nonhomogenous formulation. Together, the properties of the 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler render it highly suitable for use in the malar and chin areas. Note that in this study, very experienced investigators used the product for deep injections into the nasolabial folds, but it is not indicated or recommended for routine use in either this area or in the lips, as they require more superficial treatment. Other products, like the 24-mg/mL smooth, cohesive HA filler and other HAs are more suitable for use in these areas. Caution is also warranted when injecting additional fillers in patients who have previously been treated with synthetic polyacrylamide gel polymer fillers.
Volumizing procedures require somewhat greater skill than more superficial dermal filling procedures; specifically, that injections should be placed into the deep dermis or above the periosteum, and should be placed under the orbicularis oculi, but strictly above the deep zygomaticus. The temporal branch of the facial nerve should be avoided. Likewise, it is important to educate patients about the differences between volumizing procedures and dermal filling. Patients should be advised that swelling may occur and is not unusual. Nevertheless, 66% of the patients experienced no AEs. Observed AEs were consistent with those expected when volumizing the face and were primarily local (bruising and pain) and self-limited with a mean duration of 5.5 days.
The variations we observed in techniques, including use and type of anesthesia, needle versus cannula, planes of injection, and in injection techniques (eg, linear threading, cross-hatching, fanning) suggest that the product can be used successfully according to the individual physician's or surgeon's preference. There are advantages and limitations to both cannulas and needles, both of which are supplied with the product. For example, needle use may be easier than the cannula and may offer greater precision. Tissue trauma, however, and the risk of hematoma may be greater with multiple needle injection sites. It should be noted that these risks can be reduced by using a needle and administering only 1 or 2 injections. The cannula technique may result in less bleeding, but it looks more aggressive. This must be balanced against the potential for a lower degree of precision. In this study, very few patients required touch-ups when evaluated approximately 2 weeks posttreatment. In actual practice, we recommend evaluating for touch-ups at 1 month posttreatment to be sure that all edema, however minimal, have completely resolved and HA water absorption is complete.
This 20-mg/mL smooth, highly cohesive, viscous, fully reversible, resorbable, HA volumizing filler is indicated for restoring facial volume loss. In practice this may result from aging, congenital anatomic defects, or HIV-associated lipoatrophy.[1, 11] As shown in this study, the physical and chemical properties of the 20-mg/mL smooth, cohesive, HA volumizing filler make it robust and ideal for volumizing, yet still easy to inject, mold, and sculpt. It should be emphasized that volumizing is not a procedure to be undertaken without thorough knowledge of facial anatomy and physiology nor without proper training because it differs from the more superficial procedures with fillers. The results of this prospective evaluation of actual clinical practice demonstrate that the 20-mg/mL smooth, cohesive, HA volumizing filler provides a very effective, well-tolerated approach to volumizing an aging face. Participants did not report any occurrences of product migration, which differs from reported clinical experience with the 20-mg/mL 1,000 particle, granular consistency HA filler. The 20-mg/mL smooth, highly cohesive, viscous HA volumizing filler provided a high degree of satisfaction to patients.
Written informed consent was obtained from the patient for publication of this report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Klaus Hoffmann is a dermatologist at the St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
The Juvéderm Voluma Study Investigators Group:
Pierre André, MD, Paris, France; Benjamin Ascher, MD, Paris, France; Matilde Sánchez Bayton, DRA, Madrid, Spain; Ma Teresa Balda Etxarri, DRA, San Sebastian, Spain; Ekaterina Olegovna Gutop, MD, Jaroslav, Russia; Klaus Hebold, MD, Köln, Germany; Alexey Litvin, MD, Moscow, Russia; Leonardo Marini, MD, Trieste, Italy; Didier Potdevin, MD, CGP, Ohain (Brussels), Belgium; Adrian M. Richards, MD, Princes Risborough, England; Christopher Rowland-Payne, MD, London, England; Leonie W. Schelke, MD, CGP, Amsterdam, Netherlands; Sandrine Sebban, MD, Levallois Perret, France; Massimo Signorini, MD, Milan, Italy.
Each of the following served as study investigators: PA, BA, MSB, TBE, EOG, KH, AL, LM, DP, AMR, CRP, LWS, SS, and MS.
Funding/Support: Allergan, Inc. (Irvine, California) provided the study protocol and materials, including product, and provided funding for data analysis. Each investigator completed all study requirements and provided completed case report forms for statistical analyses by a third-party market research company, Genactis, Inc. (London, UK). Neither the authors nor participants received remuneration for their participation in the study. Allergan, Inc. provided funding for the editorial support and publication of the study; however, submission for publication was a joint decision by the lead author and funding body.
Editorial support was provided by Health Learning Systems, Parsippany, New Jersey.
- Raspaldo H: Volumizing effect of a new hyaluronic acid sub-dermal facial filler: a retrospective analysis based on 102 cases. J Cosmet Laser Ther 2008, 10: 134–142. 10.1080/14764170802154607View ArticlePubMedGoogle Scholar
- Glogau RG: Chemical peeling and aging skin. J Geriatr Dermatol 1994, 2: 30–35.Google Scholar
- Tan SR, Glogau RG: Filler esthetics. In Procedures in cosmetic dermatology series: soft tissue augmentation. Edited by: Carruthers A, Carruthers J. Philadelphia, Pa; WB Saunders Company; 2005.Google Scholar
- Rohrich RJ, Pessa JE: The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg 2007, 119: 2219–2227. 10.1097/01.prs.0000265403.66886.54View ArticlePubMedGoogle Scholar
- Shaw RB Jr, Kahn DM: Aging of the midface bony elements: a three-dimensional computed tomographic study. Plast Reconstr Surg 2007, 119: 675–681. 10.1097/01.prs.0000246596.79795.a8View ArticlePubMedGoogle Scholar
- Fagien S, Raspaldo H: Facial rejuvenation with botulinum neurotoxin: an anatomical and experiential perspective. J Cosmet Laser Ther 2007,9(Suppl 1):23–31. 10.1080/17429590701523836View ArticlePubMedGoogle Scholar
- Carruthers JDA, Glogau RG, Blitzer A: Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies—consensus recommendations. Plast Reconstr Surg 2008,121(suppl 5):5S. 10.1097/PRS.0b013e31816de8d0View ArticlePubMedGoogle Scholar
- Brisinda G, Albanese A, Cadeddu F, Bentivoglio AR, Mabisombi A, Marniga G, Maria G: Botulinum neurotoxin to treat chronic anal fissure: results of a randomized "Botox vs. Dysport" controlled trial. Aliment Pharmacol Ther 2004, 19: 695–701. 10.1111/j.1365-2036.2004.01895.xView ArticlePubMedGoogle Scholar
- Tezel A, Fredrickson GH: The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 2008, 10: 35–42. 10.1080/14764170701774901View ArticlePubMedGoogle Scholar
- Smith KC: Practical use of Juvéderm: early experience. Plast Reconstr Surg 2007,120(6 Suppl):67S-73S. 10.1097/01.prs.0000285107.16836.16View ArticlePubMedGoogle Scholar
- Bechara FG, Gambichler T, Brockmeyer NH, Sand M, Altmeyer P, Hoffmann K: Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy. Dermatology 2008, 217: 244–249. 10.1159/000148252View ArticlePubMedGoogle Scholar
- Ascher B, Coleman S, Alster T, Bauer U, Burgess C, Butterwick K, Donofrio L, Engelhard P, Goldman MP, Katz P, Vleggaar D: Full scope of effect of facial lipoatrophy: a framework of disease understanding. Dermatol Surg 2006, 32: 1058–1069. 10.1111/j.1524-4725.2006.32230.xPubMedGoogle Scholar
- Juvéderm Voluma [directions for use]. Pringy, France: Allergan 2008.Google Scholar
- Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S: A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003, 29: 588–595. 10.1046/j.1524-4725.2003.29150.xPubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-5945/9/9/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.